Experts in diabetes and eye health will discuss how the therapies used in the treatment of diabetes relate to the development and progression of diabetic retinopathy. Risa Wolf, MD, will share data that suggests GLP-1 receptor agonists can worsen diabetic retinopathy.

The COORDINATE-Diabetes trial studied the effects of prescribing three recommended classes of drugs to patients with both type 2 diabetes and atherosclerotic disease compared to standard care. Investigators including Neha Pagidipati, MD, MPH, will review the results in a Scientific Sessions symposium.

Phase 2 trial results suggest retatrutide may offer a triple therapy option to address the multiple metabolic factors that affect people who are obese, regardless of type 2 diabetes status, said Arun J. Sanyal, MD. He and other investigators will share new data on this GIP/GLP-1/glucagon receptor triagonist and its effects on obesity, type 2…

Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists are making an impact in treating patients with type 2 diabetes who may be at high risk for atherosclerotic cardiovascular disease and heart failure. Darren K. McGuire, MD, MHSc, will review both classes of drugs as part of an expert panel.

As treatments for diabetic kidney disease evolve, a panel of diabetes care experts will discuss what is happening in the world of antihyperglycemic and antihypertensive agents—and beyond—as the disease continues to be a prevalent complication from diabetes. Christine Limonte, MD, will discuss whether diabetes care professionals are following guidelines in using new therapies.

Michael Sefton, ScD, and a collaborative panel of experts will discuss cell therapy and strategies for delivering it to patients with type 1 diabetes. Topics will include identifying sites for the therapy, protecting the immune cells, and, once the cells are transplanted, monitoring the patient.

Burnout has already contributed to a reduction in the workforce dedicated to caring for patients living with diabetes. Marie Brown, MD, of the American Medical Association will explain how to effectively address clinical burnout at an organizational level using real-world examples of success centered on practice efficiency.

A panel of nephrology and diabetes experts, including Titilayo O. Ilori, MD, MSc, will discuss the impact of race, ethnicity, and underrepresentation of vulnerable populations in clinical trials in relation to diabetes and kidney disease.

During a special Saturday morning lecture, American Diabetes Association® President of Health Care & Education Janet Brown-Friday, RN, MSN, MPH, urged the medical community to be inclusive of sex and gender, race and ethnicity among staff and participants when recruiting for trials. This also includes helping make access to trials more available to participants.